Prosight Management, LP Adc Therapeutics Sa Transaction History
Prosight Management, LP
- $281 Million
- Q1 2025
A detailed history of Prosight Management, LP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Prosight Management, LP holds 9,543,004 shares of ADCT stock, worth $28.1 Million. This represents 4.79% of its overall portfolio holdings.
Number of Shares
9,543,004
Previous 9,515,000
0.29%
Holding current value
$28.1 Million
Previous $18.9 Million
28.94%
% of portfolio
4.79%
Previous 5.62%
Shares
11 transactions
Others Institutions Holding ADCT
# of Institutions
83Shares Held
53MCall Options Held
5KPut Options Held
7.6K-
Redmile Group, LLC San Francisco, CA15.7MShares$46.1 Million2.32% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$17.5 Million0.26% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$10.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.02MShares$8.88 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.8MShares$5.3 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $228M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...